Genmab — Februar 2019
-
from Celgene earnings call
In the US, POMALYST fourth quarter net sales grew 39% year-over-year, driven by the continued adoption of the triplet regiment of POMALYST, daratumumab, and dexamethasone for relapsed refractory myeloma.
https://seekingalpha.com/article/4237236-celgene-corporation-celg-ceo-mark-alles-q4-2018-results-earnings-call-transcript?part=single -
-
-
Vi har tidligere set bivirkninger fra disse PI3K hæmmere - de kæmpede jo i sin tid lidt en kamp mod BTK hæmmerne om at komme først i kombination med CD20 antistofferne. Der var i hvert fald problemer med ofatumumab i kombi med en PI3K inhibitor fra Gilead (tror jeg det var).
-
Apropos hårene i suppen: Fatal adverse reactions within 30 days of the last dose occurred in 12% (19/158) of patients treated with COPIKTRA and in 4% (7/155) of patients treated with ofatumumab. Serious adverse reactions were reported in 73% (115/158) of patients treated with COPIKTRA
-
Vi skal nok se noget markedsvækst i US for at komme væk fra den stagnationsstemning, som 0,3% US volumenstigningen Q3/Q4 skabte
-
Åååh ja, og så hjælper det heller ikke, at de store investorer, står i kø ved udgangen
-
JJ f.eks.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind